BridgeBio Pharma Current Ratio 2018-2024 | BBIO
BridgeBio Pharma current ratio from 2018 to 2024. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
| BridgeBio Pharma Current Ratio Historical Data |
| Date |
Current Assets |
Current Liabilities |
Current Ratio |
| 2024-09-30 |
$0.45B |
$0.14B |
3.19 |
| 2024-06-30 |
$0.62B |
$0.13B |
4.59 |
| 2024-03-31 |
$0.78B |
$0.14B |
5.54 |
| 2023-12-31 |
$0.48B |
$0.14B |
3.32 |
| 2023-09-30 |
$0.59B |
$0.11B |
5.54 |
| 2023-06-30 |
$0.43B |
$0.11B |
3.93 |
| 2023-03-31 |
$0.55B |
$0.10B |
5.72 |
| 2022-12-31 |
$0.55B |
$0.12B |
4.52 |
| 2022-09-30 |
$0.64B |
$0.12B |
5.39 |
| 2022-06-30 |
$0.77B |
$0.14B |
5.46 |
| 2022-03-31 |
$0.72B |
$0.10B |
6.92 |
| 2021-12-31 |
$0.89B |
$0.14B |
6.58 |
| 2021-09-30 |
$0.64B |
$0.10B |
6.68 |
| 2021-06-30 |
$0.91B |
$0.13B |
6.90 |
| 2021-03-31 |
$0.95B |
$0.10B |
9.98 |
| 2020-12-31 |
$0.64B |
$0.10B |
6.72 |
| 2020-09-30 |
$0.75B |
$0.08B |
9.85 |
| 2020-06-30 |
$0.86B |
$0.09B |
9.30 |
| 2020-03-31 |
$0.93B |
$0.07B |
14.25 |
| 2019-12-31 |
$0.57B |
$0.06B |
9.42 |
| 2019-09-30 |
$0.56B |
$0.04B |
14.00 |
| 2019-06-30 |
$0.00B |
|
0.00 |
| 2019-03-31 |
$0.00B |
|
0.00 |
| 2018-12-31 |
$0.00B |
|
0.00 |
| 2018-09-30 |
$0.00B |
|
0.00 |
| 2017-12-31 |
$0.00B |
|
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$4.260B |
$0.009B |
|
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
|
